Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.

Rini, Brian I; Garcia, Jorge A; Cooney, Matthew M; Elson, Paul; Tyler, Allison; Beatty, Kristi; Bokar, Joseph; Ivy, Percy; Chen, Helen X; Dowlati, Afshin; Dreicer, Robert

Rini, Brian I; Garcia, Jorge A; Cooney, Matthew M; Elson, Paul; Tyler, Allison; Beatty, Kristi; Bokar, Joseph; Ivy, Percy; Chen, Helen X; Dowlati, Afshin; Dreicer, Robert.

J Clin Oncol ; 28(17): e284-5; author reply e286-7, 2010 Jun 10.

Article in En | MEDLINE | ID: mdl-20439632

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/adverse effects; Carcinoma, Renal Cell/drug therapy; Kidney Neoplasms/drug therapy; Aged; Aged, 80 and over; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Bevacizumab; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indoles/administration & dosage; Indoles/adverse effects; Male; Middle Aged; Pyrroles/administration & dosage; Pyrroles/adverse effects; Sunitinib

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Combined Chemotherapy Protocols / Kidney Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2010 Type: Article

Fulltext

XML

PubMed Links

Search on Google